Weekly Digest – July 2024 Weekly Digest – July 2024 12 July 2024: FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC Mabwell’s 9MW2821, an innovative Nectin-4-targeting ADC, has […]
Weekly Digest – July 2024 Weekly Digest – July 2024 16 July 2024: Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials Sanyou Biopharmaceuticals and Huadong Medicine have announced that their jointly developed ADC drug, SYHD001, has […]
Weekly Digest – July 2024 Weekly Digest – July 2024 16 July 2024: FDA Grants Orphan Drug Designation to 7MW3711 Mabwell announced that its novel B7-H3-targeting ADC, 7MW3711 received an Orphan Drug Designation from the U.S. FDA for treating Small-Cell Lung […]
Weekly Digest – July 2024 Weekly Digest – July 2024 16 July 2024: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline SOTIO has agreed to pay Biocytogen up to $325.5 million in upfront and milestone fees […]
